Physicians' Academy for Cardiovascular Education

GLP-1 RA & CVD

Follow news, literature and expert opinions on GLP-1 as emerging target in the management of T2DM & Cardiovascular Disease

Clinical dialogue: Lowering ASCVD risk in a patient with T2DM and obesity

15' education - July 5, 2022 - Prof. Nikolaus Marx, MD and Adie Viljoen, MD

Clinical dialogue: CV risk in diabetes

15' education - June 22, 2022 - Prof. Nikolaus Marx, MD and Michael Lehrke, MD

Which patients with CKD and diabetes will benefit from management with GLP-1RA?

10' education - June 13, 2022 - Prof. Katherine Tuttle, MD

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD

GLP-1RA as new treatment option on the horizon for obesity

3' education - May 31, 2022 - Prof. Ulrich Laufs, MD, PhD

New insights and guidelines for the management of CKD and diabetes

10' education - May 31, 2022 - Prof. Johannes Mann, MD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD
5 Things a cardiologist needs to know about GLP-1RA

Role of GLP-1RA in practice

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD - Online CME
5 Things a cardiologist needs to know about GLP-1RA

How do GLP-1RAs work?

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD - Online CME

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD - Online CME
5 Things a cardiologist needs to know about GLP-1RA

Which patients to consider for GLP-1RA?

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD - Online CME

The role of GLP-1 receptor agonists in CVD prevention

10' education - Nov. 6, 2020 - Prof. Kamlesh Khunti, MD - Online CME

Introduction: Expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes

10' education - Oct. 3, 2020 - Prof. Ulf Landmesser, MD

Changing paradigm in prediabetes and CVD: Potential for new concepts and new tools

10' education - Sep. 28, 2020 - Prof. John E Deanfield, MD - Online CME

Cardiovascular outcomes & atherosclerosis: How do GLP-1RA provide benefit?

10' education - Sep. 24, 2020 - Jorge Plutzky, MD - Online CME

Panel discussion: Expanding focus for cardiologists - The diabetic patient and cardiovascular outcomes

10' education - Sep. 9, 2020 - Prof. Ulf Landmesser - Online CME

The cardiology challenge to manage CV risk in diabetes

10' education - Sep. 9, 2020 - Prof. Nikolaus Marx, MD - Online CME

Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?

10' education - July 21, 2020 - Prof. Johannes Mann, MD

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD - Online CME

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

Clinical dialogue: Lowering ASCVD risk in a patient with T2DM and obesity

15' education - July 5, 2022 - Prof. Nikolaus Marx, MD and Adie Viljoen, MD

"Multifactorial risk factor approach is important for patients with T2DM", says Adie Viljoen. He presents a case of a patient with T2DM and multiple CV risk factors. Together with prof. Marx, he discusses the treatment plan for this patient.

Clinical dialogue: CV risk in diabetes

15' education - June 22, 2022 - Prof. Nikolaus Marx, MD and Michael Lehrke, MD
Prof. Marx and Prof. Lehrke discuss a case of a 64-year old patient with T2DM and acute MI. What is the best way to address the CV risk in this patient?

Prof. Marx and Prof. Lehrke discuss a case of a 64-year old patient with T2DM and acute MI. What are the treatment options in this patient?

Substantial weight loss by dual GIP and GLP-1 receptor agonist in obese individuals

Literature - June 13, 2022 - Jastreboff AM, et al. - N Engl J Med. 2022

Tirzepatide has an agonistic effect not only on the GLP-1 receptor, but also on the glucose-dependent insulinotropic polypeptide (GIP) receptor. Whether this leads to substantial weight reduction in obese individuals without T2DM was investigated in the SURMOUNT-1 trial.

Which patients with CKD and diabetes will benefit from management with GLP-1RA?

10' education - June 13, 2022 - Prof. Katherine Tuttle, MD
In this video, Prof. Tuttle discusses GLP-1RAs for CVD risk reduction and preservation of kidney function in CKD. Moreover, she talks about multidisciplinary team care for patients with T2DM and CKD.

In this video, Prof. Tuttle discusses GLP-1RAs for CVD risk reduction and preservation of kidney function in CKD. Moreover, she talks about multidisciplinary team care for patients with T2DM and CKD.

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD
GLP-1RAs may result in beneficial effects on renal outcomes, as shown by analyses of secondary endpoints in large trials. What are the potential mechanisms leading to CVD and CKD risk reduction?

GLP-1RAs may result in beneficial effects on renal outcomes, as shown by analyses of secondary endpoints in large trials. What are the potential mechanisms leading to CVD and CKD risk reduction?

GLP-1RA as new treatment option on the horizon for obesity

3' education - May 31, 2022 - Prof. Ulrich Laufs, MD, PhD
Prof. Laufs talks about the growing problem of obesity and treatment options for people with obesity, with a focus on GLP-1 receptor agonists.

EAS 2022 Prof. Laufs talks about the growing problem of obesity and treatment options for people with obesity, with a focus on GLP-1 receptor agonists.

Fewer first strokes in T2DM patients after GLP-1RA treatment

Literature - May 31, 2022 - Strain WD et al. - Stroke. 2022

Semaglutide reduces the risk of any first stroke in T2DM patients at high CVD risk, as revealed by an exploratory post-hoc analysis of the SUSTAIN 6 and PIONEER 6 trial . History of stroke had no influence on this effect.

New insights and guidelines for the management of CKD and diabetes

10' education - May 31, 2022 - Prof. Johannes Mann, MD
Prof. Mann briefly discusses the KDIGO guidelines for treatment options in patients with T2DM and CKD. Furthermore, he provides an overview of kidney outcomes with GLP-1RAs in large trials.

Prof. Mann briefly discusses the KDIGO guidelines for treatment options in patients with T2DM and CKD. Furthermore, he provides an overview of kidney outcomes with GLP-1RAs in large trials.

Where do GLP-1RA fit in in current and future management of CKD?

Subtitling in English, German, Italian, Spanish and French

10' education - July 26, 2021 - Frederik Persson, MD - Online CME
Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities, Frederik Persson discusses future possibilities for use of GLP-1RA in other target populations.

Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities to reduce CV events, Frederik Persson discusses future possibilities for use of GLP-1RA. With question to test your knowledge.

How can GLP-1RA benefit a patient with diabetes and CKD?

Subtitling in English, German, Italian, Spanish and French

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME
There is a need for therapies for patients with low eGFR. Daniël van Raalte discusses whether GLP-1RA therapy can provide benefit for patients with T2DM and CKD.

There is a need for therapies for patients with low eGFR. Daniël van Raalte discusses whether GLP-1RA therapy can provide benefit for patients with T2DM and CKD. With question to test your knowledge.

Prevention strategies in patients with CKD and T2DM

Subtitling in English, German, Italian, Spanish and French

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME
Ofri Mosenzon discusses the importance of identification of CKD and how to prevent CKD progression in T2DM with older and newer therapeutic options.

Ofri Mosenzon discusses the importance of identification of CKD and how to prevent CKD progression in T2DM with older and newer therapeutic options. With question to test your knowledge.

Weight loss maintenance in obesity more effective with GLP-1RA and exercise than either treatment alone

Literature - June 15, 2021 - Lundgren JR, et al. - N Engl J Med. 2021

Participants with obesity had, after 1 year, more effective body weight loss maintenance with a combination of liraglutide and exercise program compared to either single treatment alone.

GLP-1 RA & CVD